Joris Rotmans, MD, PhD

Joris Rotmans mainly focuses his research on vascular access for hemodialysis. Durable vascular access is of vital importance for patients on chronic hemodialysis. Currently, complications at the vascular access site constitute a major cause of morbidity for patients with end-stage renal disease who are on hemodialysis. Most patients utilize a surgically created arteriovenous fistula (AVF) as vascular access to the bloodstream. The patency of these AVFs is limited due to the development of progressive vascular stenosis, which ultimately leads to AVF thrombosis. We developed various experimental models that allow us to unravel the specific pathophysiology of vascular stenosis in AVF. Furthermore, we are evaluating the efficacy of novel therapeutic strategies to improve vascular access durability. In example, we recently initiated a multicenter randomized clinical trial in which we assess the therapeutic effect of liposomal prednisolone to enhance AVF maturation in hemodialysis patients. In addition, we perform preclinical studies to investigate whether this targeted approach to deliver anti-inflammatory drugs is also suitable for inflammatory kidney diseases such as allograft rejection. Supported by a VIDI grant of NWO, Joris Rotmans is also working on a novel technology for in vivo vascular tissue engineering in which the foreign body response to implanted materials in used to grow autologous vascular grafts for hemodialysis access.